Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milnacipran hydrochloride 25 mg vs 50 mg starting dose in depression
CTR20140663Phase 2Active
- Sponsor
- Shanghai Shyndec Pharmaceutical
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of milnacipran in major depressive disorder (MDD), sponsored by Shanghai Shyndec Pharmaceutical. Started Oct 2014; status: active.
02
Drugs
milnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20140663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140663.